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Objective: To determine the association between the presence of anticardiolipin antibody and a history of recurrent spontaneous
abortion. Study design: clinical controlled study Location:  Department of Gynecology and Obstetrics - University of Campinas
(UNICAMP) Subjects:  52 individuals with recurrent spontaneous abortion were included in Group 1 and 104 individuals with at
least one live born child in Group 2. Elapsed time from last delivery to blood sampling varied from six months to two years.  Method :
Between November 1993 and November 1994, patients’ blood samples were screened for anticardiolipin antibody by ELISA, as
described by Triplett, Barna and Unger (1993). Analysis:  Chi-square and Fisher’s Exact tests were used for statistical analysis.
Student’s “t” test was used to compare the means. Results:  There was no statistical difference in the presence of the anticardiolipin
antibody between Group I (zero and 2.9%) and Group 2 (7.7 and 5.8%). Conclusion:  There was no association between the
presence of anticardiolipin antibody and recurrent spontaneous abortion.
Uniterms:  Anticardiolipin antibody. Recurrent spontaneous abortion. Immunology. Antiphospholipid syndrome.
INTRODUCTION
The definition of recurrent spontaneous abortion isa reproductive history of three or more spontaneousand successive abortions. It occurs at a frequency
of 0.5% to 1% of the population. There are reports on the
association of recurrent spontaneous abortion with genetic,
hormonal and uterine factors.
Antiphospholipid antibodies have been identified as
possible factors in recurrent spontaneous abortion. The most
frequently reported antiphospholipid antibody is the
anticardiolipin antibody. The association between
antiphospholipid antibodies and recurrent spontaneous
abortion is greatly recognized.1-5 Women positive to
antiphospholipid antibodies and recurrent spontaneous
abortion have better gestational results when these antibodies
are suppressed.4,6 It has been suggested that women with
recurrent spontaneous abortion or fetal death can benefit from
having circulating antiphospholipid antibody tests performed.7
The presence of antiphospholipid antibodies with clinical
manifestations such as venous and/or arterial thrombosis,
thrombocytopenia, recurrent abortion and neurological
complications is called “primary antiphospholipid
syndrome”.8 Retrospective and prospective series of pregnant
women positive to antiphospholipid antibodies show a higher
frequency of fetal death,1 especially with the IgG sub-type of
anticardiolipin antibody.9
The literature strongly suggests an association
between antiphospholipid antibodies and recurrent
spontaneous abortion but the predictive value of these
antibodies for pregnancy loss is still under debate.
Antiphospholipid antibodies may be present in normal,
successful pregnancies and may persist even beyond the
breast-feeding phase.1
Anticardiolipin antibody titration may vary during
pregnancy and an increase in its level may be related to
bad gestational prognosis.5 Persistent elevated levels have
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Table I
Results and percentage (%) distribution of
anticardiolipin antibody presence by study group
ACA Group 1 Group 2 p
Present 4   (7.7) 9   (8.7) N.S.*
Absent 48 (92.3) 95 (91.3)
Total (%) 52  (100) 104  (100)
* N.S. - Not Significant
been reported,9 and such patients have a greater risk of
complications.3
Differences in established cut-off values can determine
the variability of the results. In 1990, Love & Santoro26
reviewed 29 published series and observed that with different
cut-offs (among about 1000 systemic lupus erythematosus
patients), the prevalence of lupus anticoagulant and
anticardiolipin antibody was 34% and 44%, respectively.
Vianna et al.27 found an anticardiolipin antibody prevalence
of 14% in 95 systemic lupus erythematosus patients using a
cut-off value of 5 standard deviations,
Kwal et al.5 described women who aborted despite
immune therapy and had a dramatic increase in
antiphospholipid antibody titration when compared with
women who had live-born children. In this group titrations
remained stable or decreased at the beginning of pregnancy.
There is only one study reported in Brazil on
antiphospholipid antibodies and recurrent spontaneous
abortion.10 This study was performed to determine the
association between anticardiolipin antibody and recurrent
spontaneous abortion in a group of Brazilian patients.
METHODS
A clinical controlled study was carried out from
November 1993 to November 1994 with two groups of
patients. Group 1 included 52 patients from the Recurrent
Abortion Outpatient Clinic of the Department of
Gynecology and Obstetrics, University of Campinas
(UNICAMP). These patients had a history of three or more
successive spontaneous abortions. Group 2 included 104
patients from the Family Planning Outpatient Clinic of the
Department of Gynecology and Obstetrics, University of
Campinas (UNICAMP), during the same period. Patients
in the control group had had at least one successful
pregnancy and fulfilled the following exclusion criteria: no
history of recurrent spontaneous abortion or unexplained
fetal death; venous or arterial thromboembolic disease;
gestational hypertension or low birth weight. Elapsed time
from last delivery to blood sampling varied from six months
to two years. Patients were informed about objectives and
methodology, and signed an informed consent form.
Anticardiolipin antibodies assay
Anticardiolipin antibody was detected by enzyme-
linked immunosorbent assay (ELISA), as previously
described.11 Blood was drawn from patients without
anticoagulants and centrifuged for 10 minutes at 1600 rpm.
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Serum was stored at minus 800C and thawed at room
temperature immediately before performing the assay. The
antigen (bovine heart cardiolipin) was diluted in ethanol
(45µg/ml). 30µg of this solution was applied to the first
four rows of ELISA plate wells (96 wells, in 8 rows and
12 columns). Antigen was not added to the first column,
which remained “blank”. Another four rows were coated
with ethanol without the antigen to establish non-specific
bounding values. These values were subtracted from the
anticardiolipin coated plates to give specificity to the
method. The plates were allowed to dry overnight. 100µl
of phosphate buffered saline was added to the wells on
the next day, except for the “blank” column.  After one
minute, the phosphate-buffered saline was poured out and
the plate was beaten out over a paper towel until dry.  200µl
of phosphate buffered saline with 10% fetal calf serum
was added to all wells as a blocking buffer and incubated
for 1.5 hours. The blocking buffer reagent was then poured
out from the plates, which were once again beaten out
over a paper towel until dry. This last step was repeated
once more with a one minute incubation of phosphate-
buffered saline. 50µl of the patients’ serum was added to
all wells, except for the “blank” one and dried at room
temperature for two hours. The plates were washed three
times with 200µl of phosphate buffered saline. The plates
were dried and 50µl of indirect antibody conjugated
reagent was added to the wells, except for the blank
column. Rows one to four received conjugated IgM and
rows five to eight received conjugated IgG. After one hour
of incubation at room temperature, the plates were washed
with 200µl of phosphate-buffered saline and beaten out to
dry. 50µl of diethanolamine substrate was added to all wells
and incubated at 37ºC in the dark. The reaction was stopped
by the addition of 50µl of NaOH 3M. The optical density
was determined at 405nm in a Tibertek densitometer.
Quality control
Positive controls were taken from highly positive
samples: Dr. EN Harris’s cardiolipin standards with known
concentrations of IgG and IgM.12 A normal donor was used
as the negative control. Patients’ serum samples were run
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in duplicates. The mean result for each patient was used
as final result. The inter-assay coefficient of variation was
6.8% and the intra-assay one was 7.2%.
Interpretation of the results
Results were considered negative, intermediate,
positive and highly positive, according to the established
cut-off value. The cut-off optical density value for IgG
and IgM anticardiolipin antibody was determined for 40
normal donors. Optical density value was obtained for each
donor and means and standard deviation values were
calculated for the group. Patients’ optical density values
were compared to the cut-off. Values between 2 and 3
standard deviations were considered intermediate; positive
above 3 standard deviations and highly positive above 7
standard deviations. Results were negative when the
optical density value was less than 2 standard deviations.
The optical density cut-off value for IgM anticardiolipin
antibody was 0.17nm and for IgG anticardiolipin antibody
it was 0.20nm. Chi-square and Fisher’s Exact tests were
used for statistical analysis. Student’s “t” test was used
for comparing the means. The significance level was set
at p < 0.05.
RESULTS
The mean number of abortions was 3.75 in Group 1
(range: 3 to 8) and 78.9% were primary abortions. In Group
2, 81.7% of the patients had not had previous abortions,
while 15.4% had one and 2.9% had two abortions.
Results for anticardiolipin antibody are shown in
Table I. There was no statistical difference in
anticardiolipin antibody presence between the groups.
Group 2 had more patients with intermediate results than
Group 1, but this difference was not significant (Table II).
IgM anticardiolipin antibody was present in three patients
from Group 2 and in none from Group 1 (Table III). There
was no statistical difference in IgM anticardiolipin antibody
between groups. There was also no statistical difference
in IgG anticardiolipin antibody between Groups 1 and 2
(Table IV).  Studying sub-types of anticardiolipin antibody
(Table V), Group 1 had IgG sub-type exclusively, while
Group 2 had 66.7% of this class. This difference was not
statistically significant.
DISCUSSION
We studied the association between the presence
of anticardiolipin antibody in women’s blood and the
history of recurrent spontaneous abortion. The literature
shows that women who are recurrent spontaneous
aborters have a higher incidence of antiphospholipid
syndrome than fertile women. 7.7% of recurrent
spontaneous abortion patients had positive anticardiolipin
antibody results. These results are similar to others
reported in the literature.4  8.7% of the fertile patients
had positive anticardiolipin antibody results, which is not
in accordance with previous data.13,14
The difference in these results may be due to the
immune characteristics of this population compared to
those analyzed by other authors. Racial miscegenation
is widespread in this country and could bring about
genetic features not seen in the Caucasians who form
the majority of populations studied around the
world.7,16,17 Polyclonal activation of B lymphocytes
can also occur from intestinal flora, external aggression
and the effects of drugs.18 It is possible that this
population has not been exposed to the same immune
stimuli as in other countries.
There were no statistical significant differences in
anticardiolipin antibody levels comparing women with
recurrent spontaneous abortions (Group 1) and women
who had at least one successful pregnancy (Group 2). It
must be emphasized that 78.9% of Group 1 patients were
primary aborters. Previous data shows that women who
have the anticardiolipin antibody are mainly secondary
aborters.15 In Group 1, four women had anticardiolipin
Table II
Results and percentage (% ) distribution of
anticardiolipin antibody by study group
ACA Group 1 Group 2 p
Positive 2 (50.0) 2 (22.2) N.S.*
Intermediate 2 (50.0) 7 (78.8)
Total (%) 4 (100) 9 (100)
* N.S. - Not Significant
Table III
Results and percentage (%) distribution of IgM
anticardiolipin antibody presence by study group
IgM ACA Group 1 Group 2 p
Present - 3 (2.9) N.S.*
Absent 52 (100) 101 (97.1)
(n) 52 (100) 104 (100)
* N.S. - Not Significant
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antibody, but only two of them were secondary aborters.
The low incidence of anticardiolipin antibody in the group
of aborters may relate to the great proportion of primary
aborters. This is not acceptable because the proportion of
primary and secondary aborters is the same as previously
reported.
Another hypothesis to explain the absence of
correlation between a history of recurrent spontaneous
abortion and anticardiolipin antibody presence is technical.
The procedures used in this study were described by
Triplett et al.11 in the XIVth Congress of the International
Society for Thrombosis and Hemostasis. Dr. Harris’s
calibration serum was used for determining normal and
standard deviation values.
False-positive results can occur when non-specific
binding values are not subtracted. This may happen in
patients with hypergammaglobulinemia. To avoid it, the
absorbance of non-coated wells must be subtracted.19 The
dilution and blocking buffer used is also discussed in the
literature.20 We used fetal calf serum as blocking buffer,
as recommended in the Second International Anti-
Cardiolipin Standardization Workshop.12
Interpretation of the results was performed as
described. Triplett et al.11 suggested the expression of
results in MPL and GPL units. These are units of
measurement: GPL for IgG anticardiolipin antibody and
MPL for IgM anticardiolipin antibody. One GPL unit is
equivalent to one µg/ml of an affinity purified IgG sample;
one MPL unit is equivalent to one µg/ml of an affinity
purified IgM sample.12 We calculated means from normal
donors’ optical density, as described by Triplett et al.4
Results were expressed using standard deviations based
on these means. We chose to adopt qualitative results for
establishing a correlation between the presence of
anticardiolipin antibody and obstetric history, rather than
establishing positive result intervals as is possible when
using MPL and GPL units.
The variation of antiphospholipid antibody levels
during and after pregnancy is not well established. One
isolated sample may not reflect the real immune status
of the person. Antibody levels may increase during the
abortion process and become normal or almost normal
in the inter-gestational period.5 In this study, we
controlled the time interval between last delivery and
blood sampling for patients from Group 2, but not the
interval between last abortion and blood sampling for
patients from Group 1. This may have influenced the
results and time interval control between last abortion
and blood sampling is therefore suggested in any new
series.
We know that higher circulating antibody levels
correlate with pregnancy complications such as recurrent
spontaneous abortion.5 We decided to use 3 standard
deviations with the risk that we would have a higher
sensitivity and lower specificity and even then we did not
identify differences between the two groups.
There are other limitations when anticardiolipin
antibody results are compared in the literature. The
methods used for detection of antiphospholipid
antibodies vary in different series. Many studies involve
patients who have one or two previous abortions;22,23
etiologic factors are inclusion criteria in some studies24
whereas they are exclusion ones in others.22 “Liberal”
definitions of positive results and the lack of standards
in tests for anticardiolipin antibody and lupus
anticoagulant makes real comparison of the results
difficult. 25
Human hystocompatibility antigens (HLA) are
related to antiphospholipid antibody expression.27
Women who are prone to HLA DQ alpha 0501 develop
sub-clinical autoimmune responses in pregnancy and
may abort despite therapy.27 Kwak et al.27 consider that
there are combinations of maternal-fetal genotypes that
are unacceptable to the maternal organism, particularly
those which involve DQ alpha and DQ beta antigens.
We hypothesize that if these combinations were not
present in the group studied, the frequency of
anticardiolipin antibody positive results would be
reduced.
There is no evidence for antiphospholipid
antibodies having a causal role in abortions during the
first three months, although there is data suggesting the
Table IV
Results and percentage (%) distribution of IgG
anticardiolipin antibody presence by study group
IgG ACA Group 1 Group 2 p
Present 4 (7.7) 6 (5.8) N.S.*
Absent 48 (92.3) 98 (94.2)
Total (%) 52 (100) 104 (100)
* N.S. - Not Significant
Table V
Results and percentage (%) distribution of
anticardiolipin antibody class by study group
ACA class Group 1 Group 2 p
IgM - 3 (33.3) N.S.*
IgG 4 (100) 6 (66.7)
Total (%) 4 (100) 9 (100)
* N.S. - Not Significant
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involvement of these antibodies in the pathogenesis of
pregnancy losses.25 No matter which factors are
considered, the relationship between anticardiolipin
antibodies and pregnancy loss is conflicting.30 Our results
question the established “truths” of this association,
especially if patients are tested for anticardiolipin
antibodies (and/or lupus anticoagulant) without
associating these with other risk factors for the
antiphospholipid syndrome. The association between
anticardiolipin antibodies and recurrent spontaneous
abortion may be influenced by other factors, despite the
presence of the anticardiolipin antibody.
CONCLUSIONS
We conclude that there was no association between
anticardiolipin antibody presence and the history of
recurrent spontaneous abortion in the studied group.
7.7% of recurrent spontaneous abortion patients and
8.7% of successful pregnancy patients were positive to
anticardiolipin antibody.
There was no statistical difference in IgM
anticardiolipin antibody and IgG anticardiolipin antibody
frequencies between the studied groups.
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